Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.

L Gianni; C S Huang; D Egle; B Bermejo; C Zamagni; M Thill; A Anton; S Zambelli; G Bianchini; S Russo; E M Ciruelos; Richard Greil; V Semiglazov; M Colleoni; C Kelly; G Mariani; L Del Mastro; I Maffeis; P Valagussa; G Viale

doi:10.1016/j.annonc.2022.02.004

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.

L Gianni
, C S Huang
, D Egle
, B Bermejo
, C Zamagni
, M Thill
, A Anton
, S Zambelli
, G Bianchini
, S Russo
, E M Ciruelos
, Richard Greil (Co-author)
, V Semiglazov
, M Colleoni
, C Kelly
, G Mariani
, L Del Mastro
, I Maffeis
, P Valagussa
, G Viale

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Original Article › peer-review

231 Citations (Web of Science)

Original language	English
Pages (from-to)	534-543
Journal	ANNALS OF ONCOLOGY
Volume	33
Issue number	5
DOIs	https://doi.org/10.1016/j.annonc.2022.02.004
Publication status	Published - 2022

Keywords

PHASE-III
CHEMOTHERAPY
PACLITAXEL
PLACEBO

Access to Document

10.1016/j.annonc.2022.02.004

Cite this

Gianni, L., Huang, C. S., Egle, D., Bermejo, B., Zamagni, C., Thill, M., Anton, A., Zambelli, S., Bianchini, G., Russo, S., Ciruelos, E. M., Greil, R., Semiglazov, V., Colleoni, M., Kelly, C., Mariani, G., Del Mastro, L., Maffeis, I., Valagussa, P., & Viale, G. (2022). Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. ANNALS OF ONCOLOGY , 33(5), 534-543. https://doi.org/10.1016/j.annonc.2022.02.004

Gianni, L ; Huang, C S ; Egle, D et al. / Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. In: ANNALS OF ONCOLOGY 2022 ; Vol. 33, No. 5. pp. 534-543.

@article{9cf4a86ba138467a85cb67bdf495ad8b,

title = "Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.",

keywords = "PHASE-III, CHEMOTHERAPY, PACLITAXEL, PLACEBO",

author = "L Gianni and Huang, \{C S\} and D Egle and B Bermejo and C Zamagni and M Thill and A Anton and S Zambelli and G Bianchini and S Russo and Ciruelos, \{E M\} and Richard Greil and V Semiglazov and M Colleoni and C Kelly and G Mariani and \{Del Mastro\}, L and I Maffeis and P Valagussa and G Viale",

note = "Greil: 3rd Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria",

year = "2022",

doi = "10.1016/j.annonc.2022.02.004",

language = "English",

volume = "33",

pages = "534--543",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

publisher = "Elsevier ",

number = "5",

}

Gianni, L, Huang, CS, Egle, D, Bermejo, B, Zamagni, C, Thill, M, Anton, A, Zambelli, S, Bianchini, G, Russo, S, Ciruelos, EM, Greil, R, Semiglazov, V, Colleoni, M, Kelly, C, Mariani, G, Del Mastro, L, Maffeis, I, Valagussa, P & Viale, G 2022, 'Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.', ANNALS OF ONCOLOGY , vol. 33, no. 5, pp. 534-543. https://doi.org/10.1016/j.annonc.2022.02.004

Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. / Gianni, L; Huang, C S; Egle, D et al.
In: ANNALS OF ONCOLOGY , Vol. 33, No. 5, 2022, p. 534-543.

Research output: Contribution to journal › Original Article › peer-review

TY - JOUR

T1 - Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study.

AU - Gianni, L

AU - Huang, C S

AU - Egle, D

AU - Bermejo, B

AU - Zamagni, C

AU - Thill, M

AU - Anton, A

AU - Zambelli, S

AU - Bianchini, G

AU - Russo, S

AU - Ciruelos, E M

AU - Greil, Richard

AU - Semiglazov, V

AU - Colleoni, M

AU - Kelly, C

AU - Mariani, G

AU - Del Mastro, L

AU - Maffeis, I

AU - Valagussa, P

AU - Viale, G

N1 - Greil: 3rd Medical Department, Paracelsus Medical University Salzburg, Salzburg, Austria

PY - 2022

Y1 - 2022

KW - PHASE-III

KW - CHEMOTHERAPY

KW - PACLITAXEL

KW - PLACEBO

U2 - 10.1016/j.annonc.2022.02.004

DO - 10.1016/j.annonc.2022.02.004

M3 - Original Article

C2 - 35182721

SN - 0923-7534

VL - 33

SP - 534

EP - 543

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

IS - 5

ER -

Gianni L, Huang CS, Egle D, Bermejo B, Zamagni C, Thill M et al. Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study. ANNALS OF ONCOLOGY . 2022;33(5):534-543. doi: 10.1016/j.annonc.2022.02.004